ViaCyte receives funding towards ‘functional cure’ for diabetes
A functional cure for type 1 diabetes has been shown to be possible in non-clinical models of ViaCyte’s PEC-Encap product.
A functional cure for type 1 diabetes has been shown to be possible in non-clinical models of ViaCyte’s PEC-Encap product.
Having now secured regulatory approval for all three of its haemophilia A therapies made in Berkeley, Bayer is implementing “organisational changes” across the facility.